Related Experiment Video
Updated: Jan 21, 2026
Antibody Transfection into Neurons as a Tool to Study Disease Pathogenesis
Published on: September 26, 2012
Biology of Infection and Disease Pathogenesis to Guide RSV Vaccine Development
Seyhan Boyoglu-Barnum1, Tatiana Chirkova2, Larry J Anderson2
1Vaccine Research Center, National Institutes of Health, Bethesda, MD, United States.
Insights
Developing a respiratory syncytial virus (RSV) vaccine is challenging due to disease severity in infants and past vaccine failures. Understanding RSV proteins, like the G protein, offers new strategies for effective vaccine design to prevent disease.
Area of Science:
- * Virology and Immunology
- * Vaccine Development
- * Respiratory Tract Infections
Background:
- * Respiratory syncytial virus (RSV) is a major cause of severe lower respiratory tract illness in young children and a significant contributor to lifelong respiratory disease.
- * Despite decades of research, an effective RSV vaccine remains elusive, hindered by challenges such as the peak disease age in infants (2-4 months) and historical vaccine-related adverse events.
- * Previous attempts, like formalin-inactivated RSV with alum adjuvant (FI-RSV), have shown enhanced disease, highlighting the complexity of inducing protective immunity.
Purpose of the Study:
- * To review the roles of individual RSV proteins in viral pathogenesis and infection biology.
- * To explore how understanding these proteins can inform the development of novel live attenuated and subunit RSV vaccines.
- * To identify potential strategies for improving RSV vaccine efficacy by targeting specific viral proteins and their effects on host immune responses.
Main Methods:
- * Comprehensive literature review of existing research on RSV protein functions.
- * Analysis of the contribution of each of RSV's 11 proteins to infection and pathogenesis.
- * Evaluation of how these protein functions relate to the design principles of live attenuated and subunit vaccines.
Main Results:
- * All 11 RSV proteins play roles in infection and pathogenesis, offering targets for vaccine design.
- * The G protein is highlighted for its significant role in disease pathogenesis by modulating host immune responses and its involvement in infection biology.
- * Anti-G immunity presents a unique opportunity, potentially offering anti-inflammatory effects independent of viral replication, which could be crucial for vaccine efficacy.
Conclusions:
- * Targeting specific RSV proteins, particularly the G protein, is essential for developing effective vaccines.
- * Vaccine strategies should focus on preventing disease, not just viral replication, by considering how viral proteins modulate the host immune response.
- * Insights gained from RSV vaccine development may offer valuable strategies for other challenging vaccine targets, including influenza and HIV vaccines.
Abstract:
Respiratory syncytial virus (RSV) is a leading cause of severe lower respiratory tract disease in young children and a substantial contributor to respiratory tract disease throughout life and as such a high priority for vaccine development. However, after nearly 60 years of research no vaccine is yet available. The challenges to developing an RSV vaccine include the young age, 2-4 months of age, for the peak of disease, the enhanced RSV disease associated with the first RSV vaccine, formalin-inactivated RSV with an alum adjuvant (FI-RSV), and difficulty achieving protection as illustrated by repeat infections with disease that occur throughout life. Understanding the biology of infection and disease pathogenesis has and will continue to guide vaccine development. In this paper, we review the roles that RSV proteins play in the biology of infection and disease pathogenesis and the corresponding contribution to live attenuated and subunit RSV vaccines. Each of RSV's 11 proteins are in the design of one or more vaccines. The G protein's contribution to disease pathogenesis through altering host immune responses as well as its role in the biology of infection suggest it can make a unique contribution to an RSV vaccine, both live attenuated and subunit vaccines. One of G's potential unique contributions to a vaccine is the potential for anti-G immunity to have an anti-inflammatory effect independent of virus replication. Though an anti-viral effect is essential to an effective RSV vaccine, it is important to remember that the goal of a vaccine is to prevent disease. Thus, other effects of the infection, such as G's alteration of the host immune response may provide opportunities to induce responses that block this effect and improve an RSV vaccine. Keeping in mind the goal of a vaccine is to prevent disease and not virus replication may help identify new strategies for other vaccine challenges, such as improving influenza vaccines and developing HIV vaccines.
Related Concept Videos
01:51Vaccinations
01:03Rous Sarcoma Virus (RSV) and Cancer
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
01:20Asthma: Pathogenesis and Management
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
01:23Cystic Fibrosis: Pathogenesis
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
01:30Pulmonary Hypertension: Classification and Pathogenesis
There are various classifications for PH, each relating to different underlying causes and also...
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...